At present, the wave of innovation in the medical and health field continues to surge, and cutting-edge technologies continue to inject new vitality into clinical diagnosis and treatment. High quality medical innovation projects have become the core driving force for the development of the industry.

This issue focuses on high-quality projects in the field of biomedicine, continuing to update six high-value medical innovation achievements, covering core tracks such as small nucleic acid drugs, biomaterials, tumor therapy, and immune regulation. The technical support is solid, the clinical orientation is clear, and it accurately meets the needs of industrial layout.

Now open cooperation channels for investment institutions and industry partners!

Inviting us to work together to explore new opportunities in the field of medical and health care, and jointly explore new space for industry development!

The following is an introduction to medical assets for this period:

1、 Small Nucleic Acid | New Target Original Drug

The project focuses on the development of original drugs for the new target CREPT, and has formed a layout of “new target validation+three small nucleic acid pipelines+global patents and exit paths”. CREPT comes from more than 20 years of continuous research in the State Key Laboratory of Membrane Biology, Tsinghua University. More than 50 doctors have participated in the research for a long time. The accumulated research fund is about 50 million yuan, and it has received support from Bayer Research Transformation Fund; The team has published nearly 30 papers on this target, completed the explanation of its mechanism of action, and laid the foundation for drug development. The small nucleic acid candidate drugs targeting CREPT currently cover three pipelines: liver cancer, primary biliary cholangitis, and steatohepatitis. Some IIT projects have started clinical research in collaboration with the National Cancer Center and the GCP team of Peking University People’s Hospital, and plan to complete IND application by the end of 2026.

The core appeal of the project lies in the exclusivity of the target and the potential for future transactions. CREPT, as a direct substrate for CDK4/6, also has the potential to be used in combination with PD-1, corresponding to three scenarios of tumors, autoimmune diseases, and metabolic diseases. Currently, there are no direct competitors, and related patents cover the world, providing exclusive development and commercialization rights for the project in the Chinese and global markets. At present, the three pipelines are advancing synchronously, which not only limits the project to a single indication, but also provides richer landing points for subsequent license out and capitalization. Recently, multiple small nucleic acid projects have seen transactions at the levels of 630 million, 2 billion, and 5.2 billion US dollars, with clear international trading references for the track.

The exit path of this project is also clear: firstly, to focus on overseas patent authorization after IND completion, and sell development and commercialization rights outside of Greater China; Secondly, we will continue to promote extrahepatic delivery and clinical pipeline expansion, following the path of the Hong Kong capital market. At present, the company is the only entity in the world promoting the development of CREPT targeted drugs. The front-end has long-term basic research and hospital cooperation support, and the back-end has clear patent, clinical, and exit arrangements, which is more suitable to be understood according to the “new target platform+small nucleic acid pipeline+overseas authorization potential”.

2、 Tumor immunity | MCTL multi-target anti-tumor platform

The project focuses on the issues of single target drug resistance, limited applicable population, and large individual differences in tumor treatment, and establishes a four layer layout of “tumor target library+MCTL multi-target mechanism+cancer treatment pipeline+therapeutic vaccine cooperation”. The underlying platform has been continuously constructed since 2014, and has screened 387 highly specific tumor cluster targets covering 19 common solid tumors, involving multiple systems such as head and neck, lung, digestive, reproductive, urinary, and melanoma, providing a shared target foundation for subsequent cell drugs, therapeutic vaccines, and antibody drugs. The core mechanism of MCTL is to first detect tumor specific antigens in the patient’s serum, compare them with their own target library, identify positive targets, customize therapeutic cluster targets, rebuild immune balance through DC cells and T cells, and implement multi-target personalized therapy.

This mechanism corresponds to an integrated closed-loop of “detection+treatment”, but its current greater value lies in its ability to support the continuous development of multiple cancer treatment products and provide a platform foundation for personalized medication and recurrence resistance management in the future. At the pipeline end, the company has formed 6 MCTL anti-tumor product lines. MCTL01 is targeted at non-small cell lung cancer, and is coordinated with the first pancreatic cancer T-cell treatment project registered by the National Health Commission. It is planned to submit to IND in Q2 2026; MCTL04、 05 and 06 respectively layout liver cancer, gastric cancer, and nasopharyngeal cancer. In addition to tumor cell therapy, the company has also established a cancer vaccine technology platform and has started BD cooperation; Individualized treatment plans can further target high net worth cancer patients and specific specialized medical institutions.

The cash flow path is divided into three layers: in the short term, revenue is generated by individualized treatment of tumors and hospital cooperation; in the medium term, clinical and registration of lung cancer, colorectal cancer, pancreatic cancer and other pipelines are promoted to form a higher value node; in the long term, it is continuously expanded through cancer vaccine platform, BD cooperation and cluster target authorization. The customer base mainly includes oncology specialty hospitals, oncology departments of general hospitals, high-end medical institutions, and innovative drug companies with joint development needs. The company has obtained qualifications such as medical institution practice license, NMPA registration certificate, software copyright, invention patent, and price approval. The team covers target research, tumor clinical practice, industry operation, and business expansion.

3、 Innovative Traditional Chinese Medicine | Pulmonary Nodules

This project is an innovative traditional Chinese medicine compound for pulmonary nodules in Class 1.1. Currently, there are no approved drugs for the same indication in China. This medicine is based on classical traditional Chinese medicine theory and modern efficacy screening. It is administered orally and has the advantages of multi-target effects such as anti-inflammatory, antioxidant, and inhibition of abnormal proliferation. It is suitable for the intervention treatment of benign/inflammatory pulmonary nodules and early high-risk nodules. Animal model pharmacological validation shows that this compound can significantly reduce or eliminate lung nodules, and has good safety, making it suitable for long-term use. At present, the project has completed prescription process research, draft quality standards, and main pharmacological research, and is in the preparation stage for IND application.

From the perspective of market background, the high-risk population for pulmonary nodules in China has exceeded 150 million, and continues to grow at a rate of 10-20 million per year. The 2024 White Paper on Lung Health of Chinese Residents shows that the CT detection rate of pulmonary nodules is as high as 56%, which means that 6 out of every 10 people have pulmonary nodules. The detection rate among smokers over 50 years old is even higher at 80%. However, currently in clinical practice, pulmonary nodules can only be passively followed up and observed, without any medication to intervene in treatment. Patients are in a state of anxiety and cannot receive effective treatment for a long time, and the market demand is completely blank. The on-demand intervention population exceeds 80 million, the annual treatment cost is conservatively estimated to be 3000 yuan, and the peak market size exceeds 240 billion yuan. Currently, there are no competitors in this field, and it is expected to become the first approved pulmonary nodule treatment drug, enjoying priority review and market monopoly period.

The project team has rich experience in the registration, clinical operation, and BD exit of traditional Chinese medicine new drugs. This round of financing is 8 million yuan, with a 15% equity transfer. All funds will be used for preclinical research (efficacy, toxicology, pharmacokinetics) and preparation of IND application materials. Clear exit path: Obtain clinical approval within 2.5-3 years, with an expected transfer price of 80-100 million yuan; The transfer price after completing Phase II clinical trials is 200-300 million yuan; After completing Phase III clinical trials, it can reach 800 million to 1 billion yuan. In the future, it can also expand to overseas markets such as Southeast Asia, Japan, and Singapore.

4、 Biomedical | Cell therapy, mRNA vaccines, and fusion protein new drug platform

The project revolves around major unmet clinical needs and has formed four major technology platforms: “solid tumor immune cell therapy+mRNA therapeutic vaccines+fusion protein new drugs+synthetic biology”. It has also simultaneously laid out two business segments: innovative drugs and personalized medicine. In the core layout, the solid tumor immune cell therapy platform is based on NCK, targeting two key issues of solid tumor heterogeneity and immune microenvironment suppression, and is in the preclinical stage; The mRNA therapeutic hepatitis B vaccine project has obtained the PCT patent and has the foundation of early IIT. Early data shows that the clinical cure rate has reached 35%. Currently, IIT is being promoted and Phase I clinical work is planned to be carried out in China; The CD164 fusion protein platform has formed two key pipelines, M164 and FSH164, corresponding to endothelial injury diseases such as myocardial infarction/acute lung injury and female infertility, respectively; The synthetic biology platform revolves around full-length triple helix type I collagen and recombinant human serum albumin.

The pace of project progress and asset hierarchy are relatively clear. The hepatitis B mRNA project has lasted for nearly ten years. In the early stage, pharmacological, pharmacodynamic and some toxicological studies have been completed, and the clinical data base of the first generation VLP is available. The second generation mRNA version continues to upgrade around breaking immune tolerance, stimulating B cell and T cell responses. The ethical review has been completed and the IIT is about to be carried out, which has the possibility of entering the accelerated review by the ATMP path. M164, as a Class 1.1 innovative biological drug, has indications covering myocardial infarction, acute lung injury, and related endothelial dysfunction diseases. It has completed drug evaluation and animal data has shown improvement in heart function, reduction in myocardial fibrosis, and alleviation of pulmonary edema and inflammation in ARDS models; FSH164 has completed drug evaluation and is positioned as a long-term upgraded product in the field of female assisted reproduction. It is injected once per cycle, which is more in line with clinical compliance requirements than the existing multi needle regimen. The direction of full-length triple helix type I collagen corresponds to scenarios such as artificial skin, bone repair, and medical beauty regeneration filling. The global market is expected to grow from approximately 4.5 billion US dollars in 2025 to approximately 11.2 billion US dollars in 2032. The company is headquartered in Hangzhou and has received support from the Hangzhou Leading Talent Project. The existing R&D and operation platform covers approximately 1500 square meters, and the team has experience in new drug research and development, clinical development, review and verification, and industrialization. The subsequent promotion path includes IIT, IND application, medical conversion, and NewCo cooperative development.

5、 Innovative drugs | Flavonoids, new antibiotics, innovative drugs

The project focuses on the practical problems of bacterial resistance upgrading and the lack of new mechanism products for anti infection treatment, and establishes an antibacterial drug discovery and functional formulation platform with flavonoids as the core. The technology side has completed a continuous layout from natural molecule screening, activity verification, mechanism research to compound efficacy enhancement,

The existing results show that some flavonoid molecules have clear antibacterial and bactericidal activities against Gram positive bacteria, and the compound combination can achieve an 8-fold increase in activity. Optimization has been carried out around multiple mechanisms such as membrane damage, ion homeostasis interference, and energy metabolism inhibition. The platform is currently not limited to a single candidate drug, but simultaneously precipitates lead molecule libraries, mechanisms of action, and formulation development capabilities. In the future, it can continue to advance along anti drug resistant drugs or quickly extend to functional formulations.

The cash flow path is already quite clear. In the short term, priority can be given to converting skin and intestinal scene products, forming a faster market launch and lower regulatory threshold for revenue entry. The existing technology can correspond to the care of inflammatory dermatitis, acne control and anti-inflammatory care, intestinal microbiota regulation nutrition products, and functional health products. The customer base includes dermatology/medical beauty channels, efficacy skincare brands, nutrition and health enterprises, and pharmacy retail channels. In the medium term, it can extend to the hospital and prescription ends, and promote the development of prescription drugs for anti infection and anti drug resistant scenarios. The global acne treatment market is expected to reach $13 billion by 2027, and the global probiotics market is expected to reach $85 billion by 2027. The platform can simultaneously undertake three types of monetization scenarios: drugs, functional preparations, and consumer products. The team comes from the life science system of Xiamen University, with a foundation in natural product screening, bacterial mechanism research, and application transformation. Currently, they have a technical chassis, convertible product direction, and a landing path for multiple customer groups.

6、 Rehabilitation equipment | Interface of intelligent flexible rehabilitation robot system

The project focuses on the long-standing problems of bulky equipment, high prices, and concentrated application scenarios within and outside the hospital for the rehabilitation of stroke and lower limb dysfunction. An intelligent flexible rehabilitation robot system covering the acute, subacute, and chronic phases has been established. The technology system is centered around biomimetic human body configuration design, flexible driving control, and real-time perception interaction. It can provide CPM training, isometric and isokinetic training, and walking assistance according to different rehabilitation stages, and improve wearing comfort, motion fit, and human-machine collaboration efficiency through lightweight and flexible structures. Corresponding to hospital rehabilitation, professional training, and home-based extended rehabilitation scenarios.

Clinical feedback shows that the device performs well in terms of wearing comfort, assistance stability, and ease of operation, with corresponding customer groups including rehabilitation hospitals, comprehensive hospital rehabilitation departments, community rehabilitation centers, elderly care institutions, and rehabilitation families. The commercialization foundation of the project is based on cost structure optimization and customer scenario expansion. At present, the price of imported rigid exoskeleton products is generally in the range of 300000 to 800000 yuan, mainly serving large hospitals. Domestic similar products are also mostly concentrated in hospital configurations; The system adopts a flexible lightweight solution, with the overall weight controlled within 3kg and a target selling price of less than 30000 yuan, significantly reducing the procurement threshold and usage costs, making it more suitable for penetration into community institutions, elderly care scenarios, and households. The business model covers both direct sales and leasing operations of equipment: medical institutions and community centers can directly purchase and configure equipment, while elderly care institutions and household users can use short-term, long-term, or pay per treatment methods, thus forming a cash flow structure where equipment sales revenue and continuous service revenue are parallel.

On the market side, the scale of China’s rehabilitation medical market has exceeded 100 billion yuan, of which rehabilitation equipment accounts for about 49%; The global market size of rehabilitation medical equipment has reached 14.94 billion US dollars. The number of patients with post-stroke motor dysfunction continues to grow, and the demand for rehabilitation services is extending from hospitals to communities and families. Whether the equipment has lightweight, low-cost, and cross scenario deployment capabilities has become a key factor affecting the speed of mass production. The project plans to raise 8 million yuan, which will be used for research and development, product optimization, clinical testing and certification, small-scale production, market expansion, and liquidity replenishment. The current focus of promotion is to continue improving product performance, expanding the clinical validation foundation, and accelerating the channel introduction to the three core customer groups of hospitals, communities, and families.

This gathering includes 6 high-quality medical and health innovation projects, with cutting-edge technology as the cornerstone, clinical needs as the starting point, and market growth as the core goal. It covers innovative drugs, high-end devices, delivery technology platforms, and popular digital health tracks, and can accurately match the needs of capital investment and financing, industrial mergers and acquisitions integration, cross-border BD, and deep commercial cooperation.

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.